Type 2 Diabetes – Current Treatment – Detailed, Expanded Analysis: Physician Insights (US)

The highly genericized biguanides and sulfonylureas are, by far, the most heavily prescribed type 2 diabetes (T2D) drug classes. However, branded agents from several drug classes are jostling for position as second- and third-line treatment options. The availability of multiple effective therapies from various classes, combined with variations in prescribed combinations of drugs, physician preference for specific insulin regimens, and the launch of biosimilar insulins, has created a challenging market for developers.

QUESTIONS ANSWERED

  • How frequently are physicians prescribing combinations of T2D drugs, and which are their preferred combinations? Which factors drive or constrain physicians’ prescribing practices? What are the anticipated changes in prescribing patterns over the next 12 months?
  • What is the current patient share of GLP-1 receptor agonists such as Novo Nordisk’s Ozempic and Rybelsus and Eli Lilly’s Trulicity? What is the current patient share of SGLT-2 inhibitors such as Pfizer / Merck’s Steglatro and AstraZeneca’s Farxiga? What is the current patient share of insulins such as Sanofi’s Lantus and Eli Lilly’s Humalog?
  • How has the launch of new products such as Novo Nordisk’s Rybelsus and Pfizer / Merck’s Steglatro affected the prescribing patterns of U.S. physicians?
  • Which insulin regimens do physicians prefer to use in T2D? What percentage of T2D patients use an insulin pump versus a basal-bolus regimen?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Type 2 Diabetes - Current Treatment - Detailed, Expanded Analysis: Physician Insights (US)
    • Current Treatment Physician Insights - Type 2 Diabetes - US - July 2020

launch Related Market Assessment Reports